- Home
- ELVN vs SPH Comparison
ELVN vs SPH Comparison
Compare ELVN & SPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- SPH
- Stock Information
- Founded
- ELVN 2016
- SPH 1945
- Country
- ELVN United States
- SPH United States
- Employees
- ELVN N/A
- SPH N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- SPH Other Specialty Stores
- Sector
- ELVN Health Care
- SPH Consumer Discretionary
- Exchange
- ELVN Nasdaq
- SPH Nasdaq
- Market Cap
- ELVN 1.3B
- SPH 1.1B
- IPO Year
- ELVN 2020
- SPH 1996
- Fundamental
- Price
- ELVN $25.91
- SPH $18.39
- Analyst Decision
- ELVN Strong Buy
- SPH Hold
- Analyst Count
- ELVN 4
- SPH 3
- Target Price
- ELVN $36.75
- SPH $19.67
- AVG Volume (30 Days)
- ELVN 244.8K
- SPH 177.5K
- Earning Date
- ELVN 11-13-2024
- SPH 11-14-2024
- Dividend Yield
- ELVN N/A
- SPH 7.20%
- EPS Growth
- ELVN N/A
- SPH N/A
- EPS
- ELVN N/A
- SPH 1.14
- Revenue
- ELVN N/A
- SPH $1,327,172,000.00
- Revenue This Year
- ELVN N/A
- SPH N/A
- Revenue Next Year
- ELVN N/A
- SPH $15.78
- P/E Ratio
- ELVN N/A
- SPH $15.83
- Revenue Growth
- ELVN N/A
- SPH N/A
- 52 Week Low
- ELVN $9.80
- SPH $15.20
- 52 Week High
- ELVN $30.03
- SPH $22.33
- Technical
- Relative Strength Index (RSI)
- ELVN 41.12
- SPH 47.93
- Support Level
- ELVN $24.69
- SPH $16.94
- Resistance Level
- ELVN $26.48
- SPH $18.15
- Average True Range (ATR)
- ELVN 1.38
- SPH 0.48
- MACD
- ELVN -0.32
- SPH -0.07
- Stochastic Oscillator
- ELVN 28.35
- SPH 54.21
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About SPH Suburban Propane Partners L.P.
Suburban Propane Partners LP distributes propane, fuel oil, and other refined fuels to customers in the East Coast and West Coast regions of the United States. Other operations include natural gas and electricity marketing in the deregulated New York and Pennsylvania markets. The company operates in three segments: Propane; Fuel Oil and Refined Fuels; and Natural Gas and Electricity. It generates maximum revenue from Propane segment.